Evidence map›Paper›PMID 32967412›Full record

ArticleTurkish journal of medical sciences2021

MUC1 and MUC5AC implication in Tunisian colorectal cancer patients

Meriam Hazgui, Marwa Weslati, Rahma Boughriba, Donia Ounissi, Dhouha Bacha, Saadia Bouraoui

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The role ofContemporary oncology (Poznan, Poland) · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Meriam HazguiLaboratory of Colorectal Cancer Research UR12SP14, Mongi Slim Hospital, La Marsa, TunisiaORCID 0000-0003-2195-6469
Marwa WeslatiLaboratory of Colorectal Cancer Research UR12SP14, Mongi Slim Hospital, La Marsa, TunisiaORCID 0000-0001-5641-8754
Rahma BoughribaLaboratory of Colorectal Cancer Research UR12SP14, Mongi Slim Hospital, La Marsa, TunisiaORCID 0000-0002-6824-8307
Donia OunissiLaboratory of Colorectal Cancer Research UR12SP14, Mongi Slim Hospital, La Marsa, TunisiaORCID 0000-0003-4585-271X
Dhouha BachaDepartment of Pathology and Cytology, Mongi Slim Hospital, La Marsa, TunisiaORCID 0000-0002-8430-0072
Saadia BouraouiLaboratory of Colorectal Cancer Research UR12SP14, Mongi Slim Hospital, La Marsa, TunisiaORCID 0000-0002-9456-6878
Tunis University · TNHôpital Mongi Slim · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Mucins, such as MUC1 and MUC5AC, are known for their protective and moisturizing role in intestinal epithelium. Their expression is tightly controlled given their essential role in normal tissue homeostasis, whereas their deregulation leads to chronic inflammation, and even cancer. This study aimed to assess the expression profiles of MUC1 and MUC5AC and their implications in colorectal carcinogenesis. Materials and methods: A retrospective study of 202 patients who underwent colorectal cancer (CRC) surgery was conducted. The expression of MUC1 and MUC5AC was investigated by immunohistochemistry and reverse-transcription polymerase chain reaction (RT-PCR). Statistical analysis of mucin expression pattern, as well as the clinicopathological criteria of the patients, was performed using the chi-square test, survival curves were plotted using the Kaplan—Meier product-limit method, and differences between the survival curves were tested using the log-rank test. Results: The expression of both mucins was abnormally high in the tumor tissues for both mRNA and protein. MUC1 expression was correlated with advanced cancer stages and lymph node metastases for both the mRNA (P < 0.016 and P < 0.002, respectively) and protein level (P < 0.006 and P < 0.001, respectively). However, MUC5AC expression did not pinpoint any significant association between the clinicopathological criteria, but patients who expressed MUC5AC showed an increase in overall survival (P < 0.009). Conclusion: The expression of MUC1 might be a poor prognostic biomarker in CRC and could play a role in tumor transformation and metastasis. However, MUC5AC expression might be a good prognostic in the Tunisian cohort.

Indexed as

AdenocarcinomaColectomyColorectal NeoplasmsBiomarkers, TumorFemaleGene Expression ProfilingHumansImmunohistochemistryIntestinal MucosaKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMucin-1Mucin 5ACNeoplasm StagingBiomarkers, TumorMUC1 protein, humanMUC5AC protein, humanMucin-1Mucin 5ACColorectal cancerimmunohistochemistryMUC1MUC5ACRT-PCR

Identifiers

PMID32967412
PMCPMC7991860
OpenAlexW3088623384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.